Literature DB >> 31164387

Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring.

Nadine Wenningmann1, Merle Knapp1, Anusha Ande1, Tanaya R Vaidya1, Sihem Ait-Oudhia2.   

Abstract

Doxorubicin (DOX) is one of the most effective anticancer drugs to treat various forms of cancers; however, its therapeutic utility is severely limited by its associated cardiotoxicity. Despite the enormous amount of research conducted in this area, the exact molecular mechanisms underlying DOX toxic effects on the heart are still an area that warrants further investigations. In this study, we reviewed literature to gather the best-known molecular pathways related to DOX-induced cardiotoxicity (DIC). They include mechanisms dependent on mitochondrial dysfunction such as DOX influence on the mitochondrial electron transport chain, redox cycling, oxidative stress, calcium dysregulation, and apoptosis pathways. Furthermore, we discuss the existing strategies to prevent and/or alleviate DIC along with various techniques available for therapeutic drug monitoring (TDM) in cancer patients treated with DOX. Finally, we propose a stepwise flowchart for TDM of DOX and present our perspective at curtailing this deleterious side effect of DOX.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31164387     DOI: 10.1124/mol.119.115725

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  53 in total

1.  Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.

Authors:  Tanaya R Vaidya; Hardik Mody; Yesenia L Franco; Ashley Brown; Sihem Ait-Oudhia
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

2.  Morin Inhibits Dox-Induced Vascular Inflammation By Regulating PTEN/AKT/NF-κB Pathway.

Authors:  Jing Yu; Hai-Liang Qi; Hong Zhang; Zi-Yu Zhao; Zi-Yuan Nie
Journal:  Inflammation       Date:  2022-06-15       Impact factor: 4.092

Review 3.  The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin.

Authors:  Zaid H Maayah; Shingo Takahara; Jason R B Dyck
Journal:  Arch Toxicol       Date:  2020-08-27       Impact factor: 5.153

4.  Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.

Authors:  Veysel Özgür Barış; Adnan Berk Dinçsoy; Esra Gedikli; Selim Zırh; Sevda Müftüoğlu; Ayşen Erdem
Journal:  Cardiovasc Toxicol       Date:  2021-06-05       Impact factor: 3.231

Review 5.  Quantification of Myocardial Mitochondrial Membrane Potential Using PET.

Authors:  Matthieu Pelletier-Galarneau; Felicitas J Detmer; Yoann Petibon; Marc Normandin; Chao Ma; Nathaniel M Alpert; Georges El Fakhri
Journal:  Curr Cardiol Rep       Date:  2021-05-10       Impact factor: 2.931

Review 6.  Mitochondrial Sirtuins and Doxorubicin-induced Cardiotoxicity.

Authors:  Ling He; Fuxiang Liu; Juxiang Li
Journal:  Cardiovasc Toxicol       Date:  2021-01-12       Impact factor: 3.231

Review 7.  Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches.

Authors:  Mohammad Sheibani; Yaser Azizi; Maryam Shayan; Sadaf Nezamoleslami; Faezeh Eslami; Mohammad Hadi Farjoo; Ahmad Reza Dehpour
Journal:  Cardiovasc Toxicol       Date:  2022-01-21       Impact factor: 3.231

Review 8.  Cancer Therapy-Associated Thrombosis.

Authors:  Steven P Grover; Yohei M Hisada; Raj S Kasthuri; Brandi N Reeves; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-11       Impact factor: 8.311

9.  Chemometric Analysis of UV-Visible Spectral Fingerprints for the Discrimination and Quantification of Clinical Anthracycline Drug Preparation Used in Oncology.

Authors:  Aimen El Orche; Casimir Adade Adade; Hafid Mefetah; Amine Cheikh; Khalid Karrouchi; Miloud El Karbane; Mustapha Bouatia
Journal:  Biomed Res Int       Date:  2021-05-06       Impact factor: 3.411

10.  Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer.

Authors:  Azam Saghaeidehkordi; Shiuan Chen; Sun Yang; Kamaljit Kaur
Journal:  Pharmaceutics       Date:  2021-05-05       Impact factor: 6.525

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.